APA (7th ed.) Citation

Becker, J. C., Ugurel, S., Leiter, U., Meier, F., Gutzmer, R., Haferkamp, S., . . . Schadendorf, D. (2023). Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): Disease-free survival results from a randomised, open-label, phase 2 trial. The lancet, 402(10404), . https://doi.org/10.1016/S0140-6736(23)00769-9

Chicago Style (17th ed.) Citation

Becker, Jürgen C., et al. "Adjuvant Immunotherapy with Nivolumab Versus Observation in Completely Resected Merkel Cell Carcinoma (ADMEC-O): Disease-free Survival Results from a Randomised, Open-label, Phase 2 Trial." The Lancet 402, no. 10404 (2023). https://doi.org/10.1016/S0140-6736(23)00769-9.

MLA (9th ed.) Citation

Becker, Jürgen C., et al. "Adjuvant Immunotherapy with Nivolumab Versus Observation in Completely Resected Merkel Cell Carcinoma (ADMEC-O): Disease-free Survival Results from a Randomised, Open-label, Phase 2 Trial." The Lancet, vol. 402, no. 10404, 2023, https://doi.org/10.1016/S0140-6736(23)00769-9.